DalCor Pharmaceuticals US, LLC — SEC Form D Filing

DalCor Pharmaceuticals US, LLC filed an SEC Form D on August 28, 2026, reporting $6.96M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
August 28, 2026
Amount reported
$6.96M
Round stage
Series A because a $6.9 million equity raise is typical for an early-stage clinical biotechnology company transitioning into larger clinical trials.
Industry
Pharmaceuticals
Website
https://www.dalcorpharma.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Coronary artery disease and cardiovascular conditions require targeted, genetically-guided therapeutic interventions to reduce adverse clinical outcomes in specific patient populations.

Solution

DalCor Pharmaceuticals US conducts clinical trials and develops targeted pharmaceutical therapies aimed at treating coronary artery disease and preventing cardiovascular events.

Why now

Advancements in precision medicine and pharmacogenomics now enable researchers to target cardiovascular therapies to specific genetic profiles for higher efficacy.

Source: SEC EDGAR Form D filing